NewTherapiesSubgroup

GMMMG Greater Manchester Medicines Management Group

NHS

27th July 2010

Denosumab (Prolia®▼) for the treatment of postmenopausal osteoporosis.

The New Therapies Subgroup discussed the above drug at a meeting on 27th July 2010. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG re-considered the use of denosumab (Prolia®) for the treatment of post menopausal osteoporosis.

The group recommends that denosumab may be a treatment option in patients where bisphosphonates are contraindicated (e.g. renal patients) not tolerated or have been proven to be ineffective*

Denosumab should be initiated by a physician experienced in the diagnosis and treatment of postmenopausal osteoporosis. Costs for 1 year's treatment with denosumab are £366 per patient however it was noted that the subcutaneous injection allowed for administration in the community, unlike zolendronic acid infusion.

According to set criteria denosumab was deemed to be medium priority for funding.

** Ineffective = treatment failure*

Review date: July 2012

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.
▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.